Literature DB >> 25864110

C-reactive protein inhibits expression of N-cadherin and ZEB-1 in murine colon adenocarcinoma.

Satoshi Kudo1, Hajime Saito2, Satoru Motoyama2, Tomohiko Sasaki2, Kazuhiro Imai2, Hayato Konno2, Shinogu Takashima2, Maiko Atari2, Yusuke Sato2, Yoshihiro Minamiya2.   

Abstract

Epithelial-to-mesenchymal transition (EMT) is thought to play a key role in cancer cell invasion and metastasis. We previously demonstrated that cancer cell migration is inhibited by C-reactive protein (CRP), which is widely used as a biomarker of inflammation, though its functions are not fully understood. In the present study, we evaluated the effect of CRP on cancer cell migration and expression of mesenchymal and epithelial markers of EMT and of related transcription factors. MCA-38 murine colon adenocarcinoma cells were subcutaneously inoculated into the backs of C57BL/6 mice, which also received 1 μg of recombinant mouse CRP or vehicle (phosphate-buffered saline) subcutaneously every 3 days for 4 weeks. Thereafter, the mice were sacrificed for evaluation using quantitative real-time polymerase chain reaction (PCR) and immunohistochemistry. There was no statistical difference in tumor size between the control and CRP groups, but CRP dose-dependently inhibited MCA-38 cell migration. PCR analysis confirmed that CRP suppresses expression of N-cadherin (p < 0.01), a mesenchymal marker of EMT, and ZEB-1, an EMT-related transcription factor (p < 0.01). These findings suggest that CRP inhibits EMT in a MCA-38 tumor-bearing mouse model. CRP may thus be a potentially useful tool for preventing cancer progression through suppression of EMT.

Entities:  

Keywords:  C-reactive protein; E-cadherin; N-cadherin; ZEB-1

Mesh:

Substances:

Year:  2015        PMID: 25864110     DOI: 10.1007/s13277-015-3414-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  47 in total

1.  Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells.

Authors:  Yoshihiro Takeyama; Mitsuo Sato; Mihoko Horio; Tetsunari Hase; Kenya Yoshida; Toshihiko Yokoyama; Harunori Nakashima; Naozumi Hashimoto; Yoshitaka Sekido; Adi F Gazdar; John D Minna; Masashi Kondo; Yoshinori Hasegawa
Journal:  Cancer Lett       Date:  2010-05-07       Impact factor: 8.679

2.  The SLUG zinc-finger protein represses E-cadherin in breast cancer.

Authors:  Karen M Hajra; David Y-S Chen; Eric R Fearon
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

Review 3.  Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression.

Authors:  Thomas Brabletz; Andreas Jung; Simone Spaderna; Falk Hlubek; Thomas Kirchner
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

Review 4.  Molecular requirements for epithelial-mesenchymal transition during tumor progression.

Authors:  Margit A Huber; Norbert Kraut; Hartmut Beug
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

Review 5.  Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways.

Authors:  Lionel Larue; Alfonso Bellacosa
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

6.  DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells.

Authors:  Andreas Eger; Kirsten Aigner; Stefan Sonderegger; Brigitta Dampier; Susanne Oehler; Martin Schreiber; Geert Berx; Amparo Cano; Hartmut Beug; Roland Foisner
Journal:  Oncogene       Date:  2005-03-31       Impact factor: 9.867

Review 7.  Exploring a new twist on tumor metastasis.

Authors:  Jing Yang; Sendurai A Mani; Robert A Weinberg
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

8.  E-Cadherin mediates MMP down-regulation in highly invasive bronchial tumor cells.

Authors:  Béatrice Nawrocki-Raby; Christine Gilles; Myriam Polette; Corinne Martinella-Catusse; Noël Bonnet; Edith Puchelle; Jean-Michel Foidart; Frans Van Roy; Philippe Birembaut
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

Review 9.  Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis.

Authors:  Josef Gotzmann; Mario Mikula; Andreas Eger; Rolf Schulte-Hermann; Roland Foisner; Hartmut Beug; Wolfgang Mikulits
Journal:  Mutat Res       Date:  2004-01       Impact factor: 2.433

10.  The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity.

Authors:  K Aigner; B Dampier; L Descovich; M Mikula; A Sultan; M Schreiber; W Mikulits; T Brabletz; D Strand; P Obrist; W Sommergruber; N Schweifer; A Wernitznig; H Beug; R Foisner; A Eger
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

View more
  3 in total

1.  C-reactive protein and hepatocellular carcinoma: analysis of its relationships to tumor factors.

Authors:  Brian I Carr; Hikmet Akkiz; Vito Guerra; Oguz Üsküdar; Sedef Kuran; Ümit Karaoğullarından; Salih Tokmak; Tuğsan Ballı; Abdulalh Ülkü; Tolga Akçam; Anıl Delik; Burcu Arslan; Figen Doran; Kendal Yalçın; Engin Altntaş; Ayşegül Özakyol; Mehmet Yücesoy; Halil İbrahim Bahçeci; Kamil Yalçın Polat; Nazım Ekinci; Halis Şimşek; Necat Örmeci; Abdulalh Sonsuz; Mehmet Demir; Murat Kılıç; Ahmet Uygun; Ali Demir; Sezai Yilmaz; Yaman Tokat
Journal:  Clin Pract (Lond)       Date:  2018

2.  CRP is a superior and prognostically significant inflammation biomarker for hepatocellular cancer patients treated by liver transplantation.

Authors:  Brian I Carr; Volkan Ince; Harika Gozukara Bag; Sertac Usta; Veysel Ersan; Burak Isik; Sezai Yilmaz
Journal:  Clin Pract (Lond)       Date:  2021

3.  C-Reactive Protein-to-Albumin Ratio as Prognostic Marker for Anal Squamous Cell Carcinoma Treated With Chemoradiotherapy.

Authors:  Daniel Martin; Franz Rödel; Panagiotis Balermpas; Ria Winkelmann; Emmanouil Fokas; Claus Rödel
Journal:  Front Oncol       Date:  2019-11-08       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.